Vanda Pharmaceuticals Inc. (VNDA)

Market Cap	413.17M +57.1%
Revenue (ttm)	216.11M +8.7%
Net Income	-220.47M
EPS	-3.74
Shares Out	59.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,201,949
Open	7.19
Previous Close	7.27
Day's Range	6.98 - 7.29
52-Week Range	3.81 - 9.94
Beta	0.71
Analysts	Strong Buy
Price Target	14.90 (+113.16%)
Earnings Date	May 6, 2026

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develop...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 12, 2006
• Employees: 533
• Stock Exchange: NASDAQ
• Ticker Symbol: VNDA
• Website: https://www.vandapharma.com

Financial Performance

In 2025, Vanda Pharmaceuticals's revenue was $216.11 million, an increase of 8.72% compared to the previous year's $198.77 million. Losses were -$220.47 million, 1066.5% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for VNDA stock is "Strong Buy." The 12-month stock price target is $14.9, which is an increase of 113.16% from the latest price.

Price Target

$14.9

(113.16% upside)

Analyst Consensus: Strong Buy